Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
IntelliGenome introduces its first point-of-care (POC) molecular diagnostic solution, the CRISPR-TB POC Blood Assay*, designed to bring ultra-sensitive tuberculosis (TB) detection closer to patients. This single-test solution detects Mycobacterium tuberculosis (Mtb) DNA from nucleic acids in plasma or serum, enabling the accurate, rapid, and affordable diagnosis of both pulmonary (PTB) and extra-pulmonary tuberculosis (EPTB) across all patient groups.
Self-Contained & Simplified Testing
The CRISPR-TB POC Blood Assay is a self-contained diagnostic system with minimal sample collection and processing requirements, making it ideal for decentralized testing in clinics, rural areas, and resource-limited settings.
Building on its pioneering CRISPR diagnostic technology, IntelliGenome has developed Lab in Tube (LIT)*, an advanced point-of-care molecular diagnostic platform designed for portability, ease of use, and accessibility.
With the CRISPR-TB POC Blood Assay and LIT, IntelliGenome is revolutionizing TB diagnostics—offering a portable, accurate, and accessible solution for global TB eradication efforts.
*The CRISPR-TB Point-of-Care (POC) Blood Assay and Lab in Tube (LIT) are currently under development and have not yet received regulatory approval for diagnostic or clinical use.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.